Is Divi's Laboratories (DIVISLAB) overvalued or fairly valued?

MarketChacha shows Divi's Laboratories's valuation in context — a forward P/E of about 52.0, a price-to-book of about 11.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Divi's Laboratories's revenue?

Divi's Laboratories reported revenue of ₹10,388 Cr for FY2026, with net profit of ₹2,607 Cr, per official filings.

What is the share price of Divi's Laboratories (DIVISLAB)?

Divi's Laboratories last traded at ₹7,292.00 (-0.4% on the day), as of 7/21/2026 — a delayed quote shown for education, not investment advice.

Divi's Laboratories

DIVISLAB · NSE · Pharma · India

₹7,292.00-0.4%

Delayed · as reported by Yahoo Finance · as of Jul 21, 2026, 5:33 AM

Snapshot

TickerDIVISLAB

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees11,565

HeadquartersHyderabad, India

Market cap₹1,94,270 Cr

P/B11.6

Volume42.28K

Websitewww.divislabs.com

Filings tracked0

About Divi's Laboratories

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters52.0%
Institutions29.7%
Public & other18.3%

219 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

What's expected next

Next quarter

Rev ₹3,015 Cr · EPS 29.95

Est. earnings growth +15.3%

Next fiscal year

Rev ₹14,497 Cr · EPS 140.80

Est. earnings growth +23.2%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹5,636.5052-wk range₹7,438.50

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: BSE (official results filing)

Quarterly · last 2

Market cap

₹1,94,270 Cr

Day change

-0.4%

Fwd P/E

52.0

P/B

11.6

Div yield

0.41%

Beta

0.22

Revenue (FY2026)

₹10,388 Cr

Net margin

25.1%

EPS (FY2026)

98.19

Net profit (FY2026)

₹2,607 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about DIVISLAB

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2026	₹10,388 Cr	₹2,607 Cr	98.19	25.1%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	₹2,793 Cr	₹756 Cr	28.44	27.1%
2025Q4	₹2,578 Cr	₹598 Cr	22.56	23.2%

Figures as reported, in ₹ (crore). Source: BSE (official results filing).

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.